


WOMEN'S HEALTH MATTERS
The first summit for Gender Lens in Innovation
NOGAFem, Transforming Women's health
February 11 , 2021
18:00 IL / 17:00 CET/ 11:00 EST
The event will be held online in English Registration is free of charge Program is subject to change
The summit will be transcribed online to English
Recordings will be available to all pre-registered participants

Noa Yaffe,
Israel Innovation Authority
Opening remarks

Unmet needs of Women's Health
The impact of gender dimensions in healthcare research and technology

Prof. Valeria Raparelli MD, PhD
University of Alberta, Canada
University of Ferrara, Italy
Incorporating gender variables into research data
Covid-19 and Ischemic Heart Disease

Prof. Avi Schroeder, PhD
Technion, Israel
Nanotechnology- the impact of gender
Sex and gender in preclinical research

Dr Chandra Leo MD, MBA
HBM Partners AG
Opportunities for women's health investment

Dr. Ronell Klingman, MD
Dr. Michal Sela, DMD, MA
NOGAfem
Panel discussion: Strategies to fast track gender-lens impact into healthcare technologies to accelerate women’s health unmet needs
SUMMIT PROGRAM
.jpg)
.jpg)
Noa Yaffe, Biz Dev,
Israel Innovation Authority
Opening remarks
Lena Rogovin, Senior Digital Health Analyst
Startup Nation Central
SPEAKERS

Unmet needs of Women's Health
The impact of gender dimensions in healthcare research and technology

Incorporating gender variables into research data
Covid-19 and Ischemic Heart Disease

Prof. Avi Schroeder, PhD
Dept of Chemical Engineering Technion–Israel Institute of Technology
Nanotechnology- the impact of gender
Sex and gender in preclinical research

Opportunities for women's health investment


PANEL DISCUSSION:
Strategies to fast track gender-lens impact into healthcare technologies to accelerate women’s health unmet needs
Speakers
ABOUT THE SUMMIT
A Bit of Background
Historically research bias and representation bias has excluded women from research due to cited reasons of hormonal effects pregnancy and safety to the unborn fetus, establishing the predominant male population as the baseline.
In 2019 the FDA released the Women’s Health by 2030 plan – pushing for the inclusion of more women in clinical trials because the premise of good medicine is good evidence and that means studying diseases, technologies and medications in women
How sex and gender bias has harmed the health of women
FIRST Do no Harm is the basic tenant of the practice of good clinical medicine. Nevertheless, we still hearing about lawsuits of 1 billion dollars being paid out to women whose technologies failed them- from orthopedic implant devices to vaginal meshes? Where have our regulatory processes fallen short? What about the algorithmic bias of AI tools, resulting in inaccurate predictors of health outcomes in women?
About NOGAFem
We have established NOGAFem (R.A) to create a community of practice of researchers, entrepreneurs, innovators, investors, academic scholars and thought leaders who lead sex and gendered innovation, research, services and regulatory processes to fast track and overcome historical knowledge and practice gaps in order to facilitate healthcare equity for all genders.
About the Speakers

Prof. Karolina Kublickiene MD, PhD
-
Associate Professor in Obstetrics and Gynecology at Karolinska Institutet. Sweden.
-
Senior scientist at the Department of Clinical Science Intervention and Technology, Unit for Renal Medicine, Karolinska University Hospital.
-
Director for the Doctoral program in Development and Regeneration.
-
Founder of Gendered Innovation Alliance at KI - a platform for knowledge sharing regarding implementation of gender dimension in research and educational content towards innovations in medicine and health care.
-
PI at KI for ACT, a new Horizon 2020 EU project on Gender Equality & Gender Dimension in research.
-
PI at KI for the EU GenderNet Plus Co-Fund project: Gender Outcomes INternational Group: to Further Well-being Development (GOING-FWD).
Karolina is responsible for undergraduate and doctoral education, and the supervision of master's, PhD and Post Doc studies. Her focus is on vascular physiology and pathophysiology within the context of endothelial function. Karolina has a particular interest on women's cardiovascular health at reproductive age and after menopause and implementation of sex/gender aspects in preclinical and clinical research towards innovation in health care.
Her portfolio includes doctoral courses on Sex/gender aspects in biomedical research, methodologies in clinical research, arterial function in health and disease as well as undergraduate courses in Gender aspects in health and disease.
As a leader for the doctoral program in Development and Regeneration (DEVREG), she works to develop an excellent multidisciplinary course curriculum, but also foster initiatives from students and encourage them in collaborative and creative initiatives to become future’s innovative scientists, leaders, company developers, social entrepreneurs and teachers.

Prof. Valeria Raparelli MD, PhD
-
Assistant Professor of Internal Medicine, Department of Translational Medicine, University of Ferrara, Italy
-
Assistant Adjunct Professor University of Alberta, Faculty of Nursing, Edmonton, Alberta, Canada
-
Co-leader for the McGill coordination center of the GOING-FWD Project.
-
Co-Chair of the IMAGINE (Internal Medicine and Assessment of Gender differences in Europe) Working Group of the European Federation of
-
Internal Medicine (EFIM).
Over the past 5 years, her principal research interests have focused on understanding sex and gender- specific issues in cardiovascular disease. She was the PI on a 5-year grant entitled “Sex and gender differences in ischemic heart disease: from bench to bedside - Endocrine Vascular Disease Approach
(EVA),” at Sapienza ,University of Rome, Italy, funded by the Scientific Independence of Young Researchers (SIR) Program, promoted by the Italian Ministry of Education and the University and Research (MIUR) (2015-2020). (https://sir.miur.it/index.php/finanziati/index).
For this project, she was recently awarded the Elizabeth Young Investigator Award from the rganization for the Study of Sex Differences (OSSD).
Her current work for the International Collaboration for Gender-Oriented Research is aimed at establishing a transatlantic network of experts in gender medicine, internal medicine specialists, and outcomes researchers (GOING-FWD Consortium; https://www.mcgill.ca/going-fwd4gender/). This collaboration aims to identify appropriate measures of gender which can be feasibly applied to
evaluate chronic noncommunicable diseases. She was a visiting Professor at McGill University in Canada (2017-2019), working closely with Dr Louise Pilote to develop specific skills and knowledge in the integration and application of gender dimensions within clinical research. From March 2020, she is part of the COVID-19 Mortality Group of the Italian National Institute of Health (ISS)
(https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-analysis-of-deaths) and she is an Italian researcher partner of the iCARE (International COVID-19 Awareness and Responses Evaluation) Study (https://mbmc-cmcm.ca/covid19/).

Prof. Avi Schroeder, PhD
-
Associate Professor of Chemical Engineering Technion–Israel Institute of Technology, Haifa, Israel
Prof. Avi Schroeder is a tenured Chemical Engineering Professor at the Technion – Israel Institute of Technology and a member of Israel Young National Academy of Sciences, with a research interest at the interface of medicine and nanotechnology. He heads up the laboratory for targeted drug delivery and personalized medicine technologies. His research group is aimed at improving patients’ quality of life and bettering their treatment by developing innovative medical technologies. Specifically, the focus is on targeting metastatic cancer with nanotechnology, and on constructing miniature medical devices that couple diagnosis to therapy (theranostic devices). During his postdoctoral training at the Massachusetts Institute of Technology (MIT), he and his colleagues developed nanoparticles capable of autonomously synthesizing proteins upon signal, thereby being a platform for on-site delivery of medications and preventing damage to healthy organs. Prof Schroeder is the author of numerous scientific papers in the field of nanotechnology and medicine. In addition, Avi is the inventor of 14 patents, and recipient of 20 national and international innovation awards. He is a scientific-entrepreneur, forming five successful Technion startup companies.

Dr Chandra Leo, MD, MBA HBM Partners
Chandra joined the private equity team at HBM Partners in 2007. He has been responsible for investments in over 20 private biotech, medical device and diagnostics companies in the United States, Europe and Israel, including several firms in the field of women’s health. These companies have so far generated nine NASDAQ IPOs, five M&A transactions, and five FDA-approved marketed products.
Prior to joining HBM, Chandra worked as a postdoctoral scientist in reproductive biology at Stanford University, as a physician in OB/GYN at the University Hospital Leipzig and as a principal at Wellington Partners Venture Capital. He earned his medical degree at the Freie Universität Berlin (Charité), an MAS in Medicines Development at the University of Basel and an MBA with distinction at INSEAD.

Dr. Michal Sela, D.M.D, MA
Founder and C.O.B
High profile thought leader & Gender lecturer, with hybrid experience & knowledge on Gender equality and technology. Extensive women related policy making experience, Extensive managerial experience,
Head of the Industrial Committee at the National Council for Promoting women in science and Technology of the Ministry of Science and Technology.

Dr. Ronell Klingman (Bernstein) M.D
Founder and Board member
Medical Marketing executive with deep scientific knowledge and analytical skills.
Ronell has over 20 years’ experience in working with multinational Pharma companies.
She serves as a strategic consultant to Israeli biotech companies with a specific focus on investor decks, disease relevance and market. Hybrid knowledge and experience of medicine and technology
NOGAFEM BOARD of DIRECTORS
